Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
Disclosed are methods for treating cisplatin-induced peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a histone deacetylase 6 selective inhibitor.
1. A method of alleviating numbness associated with cisplatin-induced peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a histone deacetylase 6 selective inhibitor, to thereby alleviate the numbness associated with the cisplatin-induced peripheral neuropathy.
2. The method of claim 1 , wherein the histone deacetylase 6 selective inhibitor is compound 001:
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the histone deacetylase 6 selective inhibitor is co-administered with cisplatin.
4. The method of claim 1 , wherein the histone deacetylase 6 selective inhibitor is administered before or after administering cisplatin.
5. The method of claim 1 , wherein the cisplatin-induced peripheral neuropathy exists in the subject prior to administering the histone deacetylase 6 selective inhibitor.
6. The method of claim 1 , further comprising assessing numbness in the subject following treatment with the histone deacetylase 6 selective inhibitor.